Microdose vs standard dose: what the trials used, and where microdosing sits

The approved titration schedules are public. Microdosing is not one of them, and being straight about that is more useful than pretending otherwise.

Key takeaways

  • The approved tirzepatide schedule starts at 2.5mg weekly for four weeks and increases in 2.5mg steps to a maximum of 15mg weekly. Semaglutide for weight management steps 0.25, 0.5, 1.0, 1.7, then 2.4mg weekly.
  • Those schedules are what the trials used, so the well-known results belong to those doses and not to smaller ones.
  • Microdosing means staying deliberately below that range. No phase 3 trial has tested it, so it is a reasoned choice, not an evidence-backed one.
  • The trade is fewer side effects and a slower, smaller result. That is a real option for a modest goal and a poor one for a large one.
  • Whichever you pick, your dose is set by the prescribing provider with your labs and history in front of them.

Every large weight-loss trial of tirzepatide and semaglutide used a published, fixed titration schedule, and those schedules are printed in the FDA labeling for anyone to read. The headline results people quote come from those doses and no others.

Microdosing means deliberately staying below that range. There is no phase 3 trial of it, which means the honest description is a reasoned choice rather than an evidence-backed one.

That does not make it wrong. It makes it a trade, and the trade is worth understanding before you pick.

What the trials actually used

This is public information printed in the FDA labeling, and there is no reason for a clinic to be coy about it.

Tirzepatide begins at 2.5mg once weekly for four weeks, which is an introduction dose rather than a treatment dose. It then moves to 5mg, and can increase in 2.5mg increments after at least four weeks at each step, to a maximum of 15mg once weekly. Semaglutide for weight management follows a similar ladder: 0.25mg weekly for four weeks, then 0.5, then 1.0, then 1.7, then 2.4mg, four weeks at each step.

In SURMOUNT-1, adults on tirzepatide for 72 weeks lost on average about 15% of body weight at 5mg, about 19.5% at 10mg and about 20.9% at 15mg, against roughly 3% on placebo. In STEP 1, semaglutide at 2.4mg produced about 14.9% over 68 weeks against about 2.4% on placebo. In SURMOUNT-5, which compared the two head to head, tirzepatide came out ahead at roughly 20% against roughly 14%.

Two things follow. Those numbers describe those doses, at that duration, with the lifestyle support the trials provided. And the reason Baseline generally favors tirzepatide is not preference, it is that head-to-head result.

Where microdosing sits

Microdosing means running below the studied ladder on purpose. In practice that usually means a weekly tirzepatide dose near 2mg, under the 2.5mg approved starting dose, or a weekly semaglutide dose near 0.2mg. Those are the levels commonly used at this end of the range. The amount that applies to you is set by the prescribing provider after reviewing your history.

There is no phase 3 trial of either regimen for weight or metabolic outcomes. So here is the plain version: the mechanism is the same, the receptor activity is real at lower exposure, and the size of the effect has not been measured in a trial the way the standard doses have. Anyone quoting a specific expected weight loss for a microdose is extrapolating from a curve, not citing a study.

What is reasonably predictable is the direction of the trade-offs. Lower exposure generally means less nausea, less constipation, less appetite suppression, and a smaller and slower change on the scale, with lean mass effects unmeasured at these doses.

Which one fits which goal

The useful sorting question is the size of the goal, not the strength of the preference.

  • Under roughly 15 pounds of intended change, body composition work, or metabolic markers you want to move without a large change on the scale: a microdose is usually the sensible place to start, and the prescribing provider makes that call after reviewing your history.
  • A large amount to lose, or a history of getting stuck partway: the standard ladder is what the outcome data actually supports, and starting low to avoid it tends to just delay the same conversation.
  • A history of significant nausea or GI trouble on a GLP-1: starting lower and moving slower is a reasonable adjustment, and one your provider may make regardless of program.
  • Wanting the smallest possible dose because a bigger one feels excessive: worth talking through. Sometimes it is right, and sometimes it is a plan built to avoid a side effect that never arrives.

What does not change either way

Muscle is the thing most often lost and least often measured during weight loss, at any dose. Protein intake and resistance training are not optional extras on a GLP-1, they are what determines how much of the loss is fat.

The other constant is that your specific dose and titration are decided by the licensed provider reviewing your intake, not by a page on the internet and not by Baseline. If you move up, you move up because someone looked at your labs, your symptoms and your response, and said so.

What this means for you

Pick the dose that matches the size of your goal. Microdosing is a legitimate choice with an honest caveat, that its effect size has not been measured in a trial, and the standard ladder is the one the published results belong to.

Therapies discussed here

References

  1. FDA prescribing information, tirzepatide (Mounjaro, Zepbound), dosage and administration
  2. FDA prescribing information, semaglutide (Wegovy), dosage and administration
  3. SURMOUNT-1, tirzepatide once weekly for obesity, New England Journal of Medicine, 2022
  4. STEP 1, once-weekly semaglutide in adults with overweight or obesity, New England Journal of Medicine, 2021
  5. SURMOUNT-5, tirzepatide compared with semaglutide, New England Journal of Medicine, 2025
  6. Programs: Tirzepatide Standard and Tirzepatide Microdose

More in Before you start